The question to open with
If an answer skips your question, write down the gap and ask again. There is no need to turn uncertainty into a yes.
The FDA, the US medicine regulator, has not approved BPC-157 for any use as of September 2026.
Which official record supports the claim being made here?
Claims that need a second look
An approval claim
A business with FDA registration has entered its details in the agency’s records.
The number used to identify a drug listing is the NDC, which stands for National Drug Code.
As of September 2026, neither the claim “FDA registered” nor an NDC number shows that a medicine has FDA approval.
Ask for the medicine’s approval record rather than a registration badge.
A claim of no side effects
The FDA lacks enough information to know BPC-157’s harms in people, as of September 2026.
Ask what the statement leaves out about the size and length of the studies.
A research-only label
As of September 2026, no BPC-157 product has FDA approval for human use; a research-only label does not change that.
A claim that taking back a request made it allowed
The groups seeking FDA permission for pharmacies to use BPC-157 withdrew those requests.
As of September 2026, that did not give pharmacies permission to use BPC-157 under the federal rules for making medicine to order.
The answer needs to address the claim, rather than move on to the offer.
Keep the unresolved parts together
Save the wording of the offer, your question and the reply. If a reply is only a promise, ask for a record and a date.
A missing name, unclear fee or unanswered treatment question can stay open. Ask about other options for assessing your health concern.
Open the source drawer
These links open the documents used for this page. Ask the clinician to show you the part that supports their answer and explain anything unclear.